Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ACET | US
0.06
4.11%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
19/09/2024
1.52
1.50
1.57
1.50
Adicet Bio Inc. a clinical stage biotechnology company discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting facilitate innate and adaptive anti-tumor immune response and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001 which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002 which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925 a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio Inc. is based in Boston Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
55.1%1 month
59.9%3 months
71.7%6 months
77.9%-
-
0.52
0.08
0.07
-1.21
2.14
0.82
-121.50M
125.25M
125.25M
-
-
-
-100.00
-57.91
7.86
5.88
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.30
Range1M
0.30
Range3M
0.65
Rel. volume
0.63
Price X volume
383.92K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Zomedica Pharmaceuticals Corp | ZOM | Drug Manufacturers-Specialty & Generic | 0.13 | 129.73M | 1.96% | n/a | 1.10% |
Assertio Therapeutics Inc | ASRT | Drug Manufacturers-Specialty & Generic | 1.35 | 128.70M | 3.85% | n/a | 30.76% |
OptiNose Inc | OPTN | Drug Manufacturers-Specialty & Generic | 0.7956 | 119.96M | -6.40% | n/a | -294.40% |
Veru Inc | VERU | Drug Manufacturers-Specialty & Generic | 0.8012 | 117.28M | 4.05% | n/a | 36.36% |
Relmada Therapeutics Inc | RLMD | Drug Manufacturers-Specialty & Generic | 3.5 | 105.61M | 0.29% | n/a | 0.00% |
Karyopharm Therapeutics Inc | KPTI | Drug Manufacturers-Specialty & Generic | 0.7391 | 92.15M | 0.35% | n/a | -148.05% |
Benitec Biopharma Limited | BNTC | Drug Manufacturers-Specialty & Generic | 8.625 | 86.99M | 3.17% | n/a | 3.08% |
INC Research Holdings Inc | INCR | Drug Manufacturers-Specialty & Generic | 1.86 | 85.12M | 0.00% | n/a | 41.98% |
Silver Spike Investment Corp. Common Stock | SSIC | Drug Manufacturers-Specialty & Generic | 11.6 | 72.09M | 0.96% | 12.64 | 0.00% |
SCYNEXIS Inc | SCYX | Drug Manufacturers-Specialty & Generic | 1.63 | 61.71M | 3.82% | n/a | 25.73% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 37.9 | 107.64M | -1.76% | 5.90 | 15.58% |
Culp Inc | CULP | Textile Manufacturing | 6.35 | 79.31M | 5.31% | n/a | 11.29% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 5.78 | 62.58M | -6.47% | n/a | 54.96% |
ILAG | ILAG | Building Products & Equipment | 1.04 | 18.78M | 13.06% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.02 | 12.43M | -7.27% | n/a | 16.03% |
The Dixie Group Inc | DXYN | Textile Manufacturing | 0.737 | 11.34M | 3.80% | n/a | 422.08% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6475 | 6.16M | -2.76% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.315 | 4.97M | -1.56% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.42 | 3.63M | 1.43% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.751 | 1.10M | 24.54% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.21 | 16.67 | Cheaper |
Ent. to Revenue | 2.14 | 309.37 | Cheaper |
PE Ratio | - | 29.14 | - |
Price to Book | 0.52 | 12.81 | Cheaper |
Dividend Yield | - | 2.80 | - |
Std. Deviation (3M) | 71.73 | 75.12 | Par |
Debt to Equity | 0.08 | -0.93 | Expensive |
Debt to Assets | 0.07 | 0.45 | Cheaper |
Market Cap | 125.25M | 5.22B | Emerging |